Parexel is utilizing a real-world evidence (RWE) strategy to understand patient populations, shorten timelines, and get treatments into patient’s hands.
Parexel's Community Alliance Network, designed to more deeply integrate clinical research into community healthcare, has invited Javara and CVS as members
The two companies, which have been collaborating for 15 years, reportedly will focus on elevating decentralized trial solutions to develop new therapies.
An expert from the CRO explains the evolution of data technologies put to use in clinical studies and offers advice on how to best make them work in trials.
The global contract research organization has announced it will be purchased by Goldman Sachs Asset Management and EQT Private Equity.
The trial technology provider and contract research organization will collaborate on tech and process solutions designed to accelerate clinical studies.
The two companies will work to advance precision cancer medicine by harnessing genomics data in trial design, recruitment, site selection and other areas
The firms will work to develop solutions centered on increasing diversity and inclusivity in clinical research, and addressing healthcare disparities.
Formerly Parexel Informatics, the renamed clinical research technology company has broken off and will operate as an independent company going forward.
Industry organizations with hires, promotions, acquisitions and other news to share this month include Parexel, Novartis, WCG, Idifarma and more top firms.
Conducted via a partnership between Parexel and CISCRP, the study reveals insights about the needs and concerns of pediatric patients and their families.
The two companies will collaborate on a Phase III clinical trial investigating a potential treatment for patients hospitalized with COVID-19.
The latest analytical report from Life Science Strategy Group reveals position and perception of the leading players and performers in the eClinical arena.
The latest news on pharmaceutical industry hires, promotions, acquisitions and other events includes Medable, Eversana, Parexel, Astellas and more.
The drug discovery and pharma companies have extended their agreement to collaborate on development of new treatments for a range of therapeutic areas.
A representative from the pharma services firm discusses how increasing diversity of clinical trial populations can improve research effectiveness.
The two companies will work to develop deeper, more usable insights from healthcare data, in order to accelerate launch of clinical research studies.
Parexel is incorporating real world data into ‘all aspects’ of clinical research via multi-year strategic partnership with Datavant.
Parexel increases its real world data network by more than 330m patients across 60 health care and consumer sources though a partnership with HealthVerity – which earlier this year raised $25m to advance its technology.
Parexel’s consulting subsidiary Health Advances opens in Hong Kong to provide business strategy as well as scientific and clinical expertise to customers in the region.
Newly-minted Signant Health named a new CTO, Parexel bolstered its Japan presence, and BioAgilytix’s CEO was appointed to the board of FSD Pharma – a company developing products based on cannabinoids – among other people on the move in June.
Parexel and CluePoints to use CSM solutions for preclinical and clinical risk-based monitoring, after regulatory guidelines impact mutual acceptance of data across the US, EU and Japan.
Parexel forms a strategic partnership with Clariness to deploy the ClinLife platform in the Greater China area as the CRO looks to recruit and engage patients in their native language and via social media channels.
Parexel is opening a second US headquarters in Durham, NC, a move which will see the addition of 264 jobs as part of the $1.7m investment.
Parexel today unveiled its Oncology Center of Excellence as well as a new “early advisory service” focused on study design, regulatory strategy, and market access.
Parexel Biotech will support emerging companies from development through commercialization with tailored services and customized guidance, says division lead.
Parexel and Eli Lilly are launching a clinical research learning and development program in China as recent reforms have “dramatically” increased the need for new sites in the country.
Moving forward, China will take a more integral role in global drug development, following several regulatory changes designed to accelerate innovation.
Parexel is adopting Medidata’s Shyft Analytics platform to bolster its real-world evidence generation and outcomes research offering to biopharmaceutical and medical device clients.
CROs this month have made significant new hires with WCG adding eight to its scientific leadership team, PPD hiring four, and BioIVT filling its new-created role of CCO.
Also, making the move from Bioclinica, David Kiger has been named...
Parexel is launching a new advisory service to help clients navigate the market opportunities in China.
The global biopharmaceutical services provider has launched the Patient Innovation Center to help sponsors implement patient-centric initiatives — an area in which the company is committed to innovate, says executive.
Innovations in drug development positively affect clinical trial timelines, market launch likelihood, and patient access – though adoption remains low, says report.
Another day, another CRO acquisition – this time Parexel, a top 10 CRO, was acquired by Pamplona Capital, a large private equity firm.
CRO Parexel’s staffing numbers took center stage during its earnings call Thursday as the company re-iterated plans to lay off as many as 850 employees – mostly in higher-cost countries -- to increase its margins.
CRO Parexel on Wednesday announced the expansion of its clinical trial site alliance network, which includes investigator sites and Site Management Organizations (SMOs) that help the company quickly access and enroll patient populations for clients’ clinical...
Parexel says it is looking to acquire technology or consulting companies and may select a small firm in the Middle East or Turkey.
Gross bookings at Parexel topped $1bn in the third quarter but the need to accelerate hiring again led to a cut to earnings guidance.
Parexel adds imaging tech for early phase CNS research
Parexel has added functional magnetic resonance imaging technology (fMRI) to its early phase units to advance CNS research.
Parexel cuts guidance & Phase I capacity after weak results
Parexel has slashed its guidance and is cutting early phase capacity after weak results, but hiring in other areas is accelerating.
CROs will support sponsors through unprecedented change
Pharma is going through an absolutely unprecedented, once in an industry sea change, says Parexel, and CROs will play a key role in the process.
Parexel adds offices in China
Parexel has opened two offices in China, expanding its presence in Asia Pacific to 17 sites, as part of efforts to provide cheaper, faster drug development services.
Parexel opens another early phase unit in South Africa
Parexel has opened a 40 bed early phase clinical trial unit in South Africa, increasing its Phase I capabilities in the country and adding to its patient recruitment focused SuperSites network.
Accounting errors impact on Parexel in 09
Accounting errors related to the purchase of ClinPhone reduced Parexel’s operating income by $15.9m (€11.2m) in fiscal 2009 and the impact of these charges will continue into the next year.
Parexel’s cancellations double as profit growth stalls
Parexel posted a doubling in cancellations in Q3 of its fiscal year, with profits remaining flat as an eight per cent boost in service revenue was offset by higher operating expenses.
Parexel on the up as 2Q figures impress
Contract research company Parexel saw its share rocket more than 30 per cent yesterday after it reported a hike in its second quarter revenues and despite a fallback in net profits.
Parexel cuts revenue forecasts as earnings dip
Contract research organisation Parexel posted a 26 per cent hike in first quarter revenues to $263m but still failed to meet its own internal sales targets and saw net profits slide.
ClinPhone has Parexel purchase in sight
Only months after having its first offer rejected, ClinPhone has
finally agreed to a deal allowing Parexel to acquire the firm.
However Quintiles has indicated it may make a play to outbid its
Parexel profits perky in Q1
Parexel has seen its profits remain perky during its first
financial quarter of 2008.
Parexel angling to dominate Phase I arena
Paraxel has acquired a $65m (€52m) US business that will inflate
its early phase capacity enough to make it one of the largest
providers of Phase I services in the world and help "return its US
operations to profitability".